Drug intelligence / Profile preview

Z-VLL-CHO

Development stage: Unknown
Modality: Peptides, Small Molecules
Administration: In Vitro

Overview

Z-VLL-CHO is a **cell-permeable, reversible peptide aldehyde inhibitor of beta-secretase (BACE1)**, characterized as N-benzyloxycarbonyl-Val-Leu-leucinal. It acts by competitively binding to the active site of beta-secretase, thereby inhibiting the cleavage of amyloid precursor protein (APP) and reducing the production of beta-amyloid peptides. This property makes it a valuable chemical probe in Alzheimer's disease research and in studies investigating beta-secretase function in various biological processes. In addition to its core use as a research tool, Z-VLL-CHO has been shown to modulate heparan sulfate 6-O-sulfation by altering the activity of heparan sulfate 6-O-sulfotransferase 3 (HS6ST3)[4][5].

Other names: beta-secretase inhibitor II

Targets

BACE1 (Beta-site APP-cleaving enzyme 1)

Beyond the preview

Go deeper on Z-VLL-CHO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Z-VLL-CHO.

Explore the full profile